Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EUDA Health Holdings Limited filings document a foreign private issuer with ordinary shares and listed warrants, using Form 6-K reports to disclose material events, Nasdaq listing-compliance notices, capital actions, securities purchase agreements and warrant matters. The filings include disclosures on a board-approved reverse stock split, adjustments to warrant terms, a registered ordinary-share offering under a Form F-3 shelf registration statement, and the repurchase and cancellation of a warrant.
EUDA's regulatory reports also describe its healthcare activities in Asia, including a non-exclusive arrangement to market selected Shenzhen Inno immunotherapies to customers in Malaysia through CK Health Plus Sdn Bhd, with treatments conducted in China.
EUDA Health Holdings filed a prospectus supplement to amend its prior ATM registration, reducing the maximum aggregate offering price to $10.0 million and suspending further sales under the ATM Agreement. The company states that no ordinary shares have been sold under the ATM Agreement as of the date of this Supplement. The company notified the manager on June 5, 2026 of its intent to terminate the ATM Agreement; the termination becomes effective 30 business days after that notice per the agreement. The supplement notes the Nasdaq closing price of the ordinary shares was $15.50 on June 11, 2026.
EUDA Health Holdings Limited is suspending and terminating its at-the-market equity offering program with Chardan Capital Markets LLC. The company had the ability to offer and sell up to $10,000,000 of ordinary shares under an At The Market Offering Agreement and related prospectus supplements.
EUDA sent a termination notice for the ATM Agreement on June 5, 2026, with termination to take effect on July 22, 2026 after a 30-business-day period. The ATM Offering has been suspended effective June 10, 2026, and EUDA plans to file a prospectus supplement reducing the number of shares offered to zero. As of this report, no ordinary shares have been sold under the ATM program.
EUDA Health Holdings Ltd reports an amended Schedule 13G showing beneficial ownership by Tan Meng Dong (James) and 8i Capital Limited. Mr. Tan beneficially owns 459,130 ordinary shares, equal to 15.3% of the outstanding ordinary shares; this total includes 340,631 shares held directly, 111,193 shares held by 8i Capital Limited, and 7,306 shares underlying warrants. The filing states 2,994,325 ordinary shares outstanding as of May 22, 2026. The statement notes that Mr. Tan is sole shareholder and director of 8i Capital Limited and that the parties filed a Joint Filing Agreement to report ownership jointly.
EUDA Health Holdings Ltd Schedule 13G reports that Zhang Xin beneficially owns 295,000 ordinary shares, representing 9.85% of the class. The filing states shares outstanding were 2,994,325 ordinary shares as of May 22, 2026.
The filing lists sole voting and sole dispositive power over the 295,000 shares. The document is a passive ownership disclosure under Schedule 13G and does not describe transactions or transfers within the excerpt.
EUDA Health Holdings Limited has expanded its Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask, a premium beauty mask developed by Chemokine Pte Ltd. EUDA holds exclusive global distributorship rights for Helixé products from Chemokine.
The Regenixé Mask uses iPSC-derived skin stem cell secretome and cellulose mask technology, aimed at supporting skin hydration, brightening, and overall recovery. EUDA plans to leverage its existing distribution networks and wellness partnerships in Malaysia and China to drive sales across the Asia-Pacific region.
Management cites industry research indicating the global face mask market could reach about US$9.08 billion by 2031, with Asia-Pacific as a leading region. This launch aligns with EUDA’s broader strategy in non-invasive, preventive healthcare and longevity-focused consumer products in Asia.
EUDA Health Holdings Limited reported that it has regained compliance with the Nasdaq Capital Market’s continued listing requirements related to market value. Nasdaq had previously notified EUDA on April 23, 2026 that its Market Value of Listed Securities was below the required $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). A subsequent Nasdaq notice on May 28, 2026 confirmed that EUDA’s Market Value of Listed Securities was $35 million or greater for ten consecutive business days from May 13 to May 27, 2026, restoring the Company’s compliance with the MVLS standard.
EUDA Health Holdings Limited filed a Form 6-K highlighting that Shenzhen Inno Immune Co., Ltd. has received official approval under the 2025 Shenzhen Key Industry R&D Program for a TCR-T cell therapy project targeting solid tumors.
The project is scheduled to run from January 1, 2026 to December 31, 2028 and may receive up to approximately US$434,688 in government funding from the Shenzhen Science and Technology Innovation Bureau. Under a non-exclusive distribution arrangement, EUDA holds rights to market and sell selected Shenzhen Inno immunotherapies to customers in Malaysia via its subsidiary CK Health Plus Sdn Bhd, with treatments conducted in China.
Management explains that this aligns with EUDA’s strategy to expand access to advanced, science-driven therapies and supports its broader focus on preventive and longevity-focused healthcare across Asia.
EUDA Health Holdings Limited files its annual Form 20-F for the year ended December 31, 2025, highlighting ongoing financial strain and strategic shifts. The company reports a net loss of approximately $2.8 million for 2025, following a $15.4 million loss in 2024, and discloses a working capital deficit of about $4.8 million with only $0.3 million in cash.
EUDA’s auditor raises substantial doubt about its ability to continue as a going concern, and management acknowledges material weaknesses in internal control over financial reporting. Nasdaq has notified the company that it failed to maintain the required $35 million Minimum Market Value of Listed Securities; EUDA must regain compliance by October 20, 2026 to avoid potential delisting.
The report describes a strategic move from medical services to wellness, including the $15.0 million all-share acquisition of CK Health, which generated roughly $2.0 million of 2025 revenue, and reliance on Southeast Asian wellness and planned stem cell offerings. EUDA also details multiple equity and convertible financings, a 1-for-20 reverse stock split, and an agreement to purchase 16 million QB utility tokens using cash and shares, underscoring its need for ongoing external funding.
EUDA Health Holdings Limited reported that Nasdaq notified the company on April 23, 2026 that it failed to maintain the required Minimum Market Value of Listed Securities of $35 million for 32 consecutive business days under Nasdaq Listing Rule 5550(b)(2). The notice does not immediately affect trading, and EUDA has 180 calendar days, until October 20, 2026, to regain compliance by having its market value close at $35,000,000 or more for at least ten consecutive business days. If EUDA does not regain compliance within this period, its securities will be subject to potential delisting, although the company would have the right to appeal.
EUDA Health Holdings Limited approved and is implementing a 1-for-20 reverse stock split of its ordinary shares, effective at market open on March 23, 2026 on the Nasdaq Capital Market. The company states that shareholder ownership percentages and voting power will remain substantially the same aside from minor rounding effects.
Shares outstanding will be reduced from approximately 50,307,491 to approximately 2,515,375, with fractional shares rounded up and no cash paid in lieu. EUDA’s outstanding warrants will be adjusted proportionately, cutting underlying shares from about 4,458,625 to about 222,932 while increasing the exercise price from $11.50 to $230.00 per share equivalent.